C&Y Pharmaceutical(SZ:300254)2025-05-20 10:52Group 1: R&D Investment and Achievements - In 2024, the company's R&D expenses reached CNY 56.53 million, representing a year-on-year increase of 13.19% [2] - Key R&D projects include the approval of the drug "Perindopril" in December 2024 and the development of "Maltose Iron Gel" [2] Group 2: Financial Performance - In 2024, the company achieved an operating income of CNY 847 million, a growth of 5.92% year-on-year, and a net profit attributable to shareholders of CNY 42.19 million, up 67.45% [5] - The increase in performance was driven by revenue growth, reduced financial expenses related to financial liabilities, and increased government subsidies [5] Group 3: Market Position and Future Plans - The company is focusing on multi-channel sales strategies for its smoking cessation drug, with expectations of continued high growth this year [6] - There are currently three companies competing in the domestic market for smoking cessation drugs [6] - The company has no current plans for mergers or acquisitions but will disclose any future plans promptly [6] Group 4: Shareholder Engagement and Financial Health - The decline in net assets is primarily due to the acquisition of minority shareholder equity in a subsidiary and obligations related to share buybacks [4] - The company emphasizes balancing profit distribution with reinvestment needs to enhance investor confidence [5]